866-997-4948(US-Canada Toll Free)

Cerus Corporation (CERS) - Product Pipeline Analysis

Published By :

GlobalData

Published Date : Nov 2012

Category :

Surgical Equipment

No. of Pages : 44 Pages


Cerus Corporation (Cerus) is a biomedical products manufacturing company which undertakes the development and commercialization of novel, proprietary products and technologies, intended to make the blood supply safer. The company focuses on the development and commercialization of INTERCEPT Blood System based on its proprietary Helinx technology. Cerus holds the worldwide rights of INTERCEPT for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It is a pathogen inactivation system that is being marketed in Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis and actionable intelligence on the Cerus Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 3
List of Figures 4

Cerus Corporation - Business Description 5

Key Facts 6
Cerus Corporation - Major Products and Services 7
Cerus Corporation Pipeline Products by Equipment Type 8
Cerus Corporation Pipeline Products by Development Stage 10
Cerus Corporation Pipeline Products by Therapy Area 12
Cerus Corporation Pipeline Products by Trial Phase 14
Cerus Corporation Pipeline Products by Milestone Summary 16
INTERCEPT Blood System - Platelets 18
INTERCEPT Blood System - Platelets Product Status 18
INTERCEPT Blood System - Platelets Product Description 18
INTERCEPT Blood System - Platelets Product Milestone 18
INTERCEPT Blood System - Platelets Clinical Trial 19
INTERCEPT Blood System For Red Blood Cells 26
INTERCEPT Blood System For Red Blood Cells Product Status 26
INTERCEPT Blood System For Red Blood Cells Product Description 26
INTERCEPT Blood System For Red Blood Cells Product Milestone 26
INTERCEPT Blood System For Red Blood Cells Clinical Trial 28
Intercept Plasma System - TTP 29
Intercept Plasma System - TTP Product Status 29
Intercept Plasma System - TTP Product Description 29
Intercept Plasma System - TTP Product Milestone 30
Intercept Plasma System - TTP Clinical Trial 31
Cerus Corporation - Key Competitors 35
Cerus Corporation - Key Employees 36
Cerus Corporation - Key Employee Biographies 37
Cerus Corporation - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Cerus Corporation, Recent Developments 39
Nov 07, 2012: Cerus Reports Revenue Of $8.3m In Q3 2012 39
Aug 02, 2012: Cerus Reports Total Revenue Of $9.2m For Q2 2012 40
May 01, 2012: Cerus Reports Revenue Of $8.8m In Q1 2012 40
Apr 03, 2012: Cerus Announces New Supply Agreement With King Faisal Specialist Hospital In Saudi Arabia 41
Feb 28, 2012: Cerus Reports Revenue Of $10.4m In Q4 2011 41
Feb 01, 2012: Cerus And Ilex BioTech Report INTERCEPT Platelet And Plasma System Approvals In Israel 42
Jan 09, 2012: Cerus Appoints Andrew Gomperts As Chief Business Officer 42
Dec 06, 2011: Cerus Signs New Agreement With Russias FMBA For New INTERCEPT Blood System Illuminators 42
Nov 10, 2011: Cerus Signs New Agreement With French National Blood Service To Supply INTERCEPT Blood System Disposable Kits For Platelets And Plasma 43
Nov 01, 2011: Cerus Reports Revenue Of $9m In Q3 2011 43

Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Table


Cerus Corporation, Key Facts 1
Cerus Corporation Key Pipeline Products by Equipment Type 1
Cerus Corporation Key Pipeline Products by Therapy Area 1
Cerus Corporation Key Pipeline Products by Development Stage 1
Cerus Corporation Key Pipeline Products by Trial Phase 1
Cerus Corporation, Key Facts 6
Cerus Corporation, Major Products and Services 7
Cerus Corporation Number of Pipeline Products by Equipment Type 8
Cerus Corporation Pipeline Products by Equipment Type 9
Cerus Corporation Number of Pipeline Products by Development Stage 10
Cerus Corporation Pipeline Products by Development Stage 11
Cerus Corporation Number of Pipeline Products by Therapy Area 12
Cerus Corporation Pipeline Products by Therapy Area 13
Cerus Corporation Number of Pipeline Products by Trial Phase 14
Cerus Corporation Pipeline Products by Trial Phase 15
Cerus Corporation Number of Pipeline Products By Milestone Summary 16
Cerus Corporation Pipeline Products by Milestone Summary 17
INTERCEPT Blood System - Platelets - Product Status 18
INTERCEPT Blood System - Platelets - Product Description 18
INTERCEPT Blood System - Platelets - Product Milestone 18
INTERCEPT Blood System - Platelets - A Prospective Observational Cohort Safety Study Of 5106 Platelet Transfusions With Components Prepared With Photochemical Pathogen Inactivation Treatment 19
INTERCEPT Blood System - Platelets - A Randomized, Controlled, Double-Blinded Trial on INTERCEPT Blood System-Plasma, Preparing The Buffy Coat Platelets 20
INTERCEPT Blood System - Platelets - Routine Production Of Intercept-Treated Apheresis Platelet Concentrates For Pediatric Patients 21
INTERCEPT Blood System - Platelets - Impact Of Photochemical Treatment (Intercept) On Platelet Use In Routine Practice 22
INTERCEPT Blood System - Platelets - Inactivation Of High Levels Of Bacteria Using The Intercept Blood System Under Routine Blood Bank Procedures 23
INTERCEPT Blood System - Platelets - Therapeutic Efficacy And Safety Of Transfusion Of Pathogen-Inactivated Platelets To Pediatric Patients 24
INTERCEPT Blood System - Platelets - Transfusion Of Pathogen Inactivated Platelet Concentrates In Children 25
INTERCEPT Blood System For Red Blood Cells - Product Status 26
INTERCEPT Blood System For Red Blood Cells - Product Description 26
INTERCEPT Blood System For Red Blood Cells - Product Milestone 26
INTERCEPT Blood System For Red Blood Cells - Phase I Trial For INTERCEPT Red Blood Cell System 28
Intercept Plasma System - TTP - Product Status 29
Intercept Plasma System - TTP - Product Description 29
Intercept Plasma System - TTP - Product Milestone 30
Intercept Plasma System - TTP - Stability Of Coagulation Factors In Plasma Prepared With Photochemical Treatment (INTERCEPT) Stored For One Year 31
Intercept Plasma System - TTP - Photochemical Pathogen Inactivation Of High-Dose Apheresis Platelet Concentrates Using The Intercept Blood System 32
Intercept Plasma System - TTP - Inactivation Of Chikungunya Virus In Plasma And Platelets Using Helinx Technology, As Utilized In The Intercept Blood System 33
Cerus Corporation, Key Employees 36
Cerus Corporation, Key Employee Biographies 37
Cerus Corporation, Subsidiaries 38

List of Chart


Cerus Corporation Pipeline Products by Equipment Type 8
Cerus Corporation Pipeline Products by Development Stage 10
Cerus Corporation Pipeline Products by Therapy Area 12
Cerus Corporation Pipeline Products by Trial Phase 14
Cerus Corporation Pipeline Products by Milestone Summary 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *